SONEAS Chemicals

What SONEAS Chemicals does

SONEAS Chemicals Ltd. (legal name: SONEAS Vegyipari Kft.) is a Budapest-headquartered Contract Development and Manufacturing Organization (CDMO) founded in 1996 and operating as a member of the Spanish Uquifa Group since 2018. The company provides end-to-end chemical services to originator pharmaceutical companies and innovative biotech firms, spanning discovery chemistry, process research and development, cGMP-compliant API and intermediate manufacturing, and commercial-scale production of intermediates and specialty chemicals. Three unique process technology platforms—hydrogenation (with reactors up to 3,000 liters), hydroxyethylation using ethylene and propylene oxide, and E/Z-selective metathesis using Mo, W, and Ru catalysts in glove-box environments—form the technical differentiators that allow access to chemical entities difficult to achieve through conventional transformations. Services are delivered from three Budapest sites: R&D laboratories at Berlini utca, a kilo-lab/pilot/cGMP plant and analytical laboratories at the Illatos út headquarters, and an ISO 9001 (TÜV) certified large-scale manufacturing facility at Bányalég utca, with an aggregate production capacity of 208,000 kg.

SONEAS serves two customer segments: pharmaceutical companies (primary) requiring API development and manufacturing from preclinical through Phase III and commercial supply under EMA and NNGYK oversight, and non-pharmaceutical fine chemical customers requiring ISO 9001 certified custom synthesis. The company holds EMA certification and is regularly inspected by NNGYK; its Illatos site operates under cGMP (EudraLex Vol. 4 and ICH guidelines) while the Bányalég utca site operates under ISO 9001. Revenue is generated through two pricing models—Full-Time Equivalent (FTE) engagements for mid-to-long-term dedicated scientific staffing, and Fee-for-Service/Fixed Fee (FFS) project-based billing—both multi-year contracts. Go-to-market is direct enterprise sales led by a Business Development and Project Management organization, complemented by industry trade-show presence (CPhI, Discovery US/EU, Chemspec) and content marketing via brochures and Pharma Tech Outlook placement.

Operationally, SONEAS positions itself as a preferred nearshoring partner for European and global pharmaceutical customers, with 25+ years of track record. There is no public ownership, no disclosed headcount trend, no revenue figure, and no recorded funding event beyond a 2012 Euroventures round; the company remains privately held under Uquifa Group with 11-50 employees.

Name

SONEAS Chemicals

Legal name

SONEAS Vegyipari Kft.

Website

https://soneas.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

SONEAS Chemicals is a Budapest-based European CDMO providing end-to-end API development and manufacturing—from discovery chemistry through cGMP clinical and ISO 9001 commercial-scale production—primarily for originator pharmaceutical companies, with differentiated hydrogenation, hydroxyethylation, and metathesis technologies. The company has operated since 1996 and is a member of Spain's Uquifa Group since 2018.

Ownership category

akta.pro rank

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract pharmaceutical manufacturing
• Custom chemical synthesis
• API process development
• CGMP manufacturing services
• Pharmaceutical intermediates

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices4 records

Markets served

Revenue model

1. CDMO Services - Discovery and Development: Early phase chemical development services including discovery chemistry, lead optimization, and process R&D. Billed through FTE (Full-time Equivalent) or Fee-for-Service/Fixed Fee models.
2. cGMP Manufacturing: Manufacturing of APIs and intermediates under cGMP conditions for clinical trials (Phase 1 to 3) and commercial supply. Revenue generated from custom synthesis projects.
3. Large Scale Manufacturing: Commercial-scale manufacturing of intermediates, starting materials, and specialty chemicals for pharmaceutical and non-pharmaceutical applications under ISO 9001 standards.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

SONEAS Chemicals is a Hungarian contract development and manufacturing organization (CDMO) that provides custom synthesis, process research and development, and cGMP manufacturing of active pharmaceutical ingredients (APIs), intermediates, and starting materials. The company serves pharmaceutical innovators and generics manufacturers across the full development lifecycle, from gram-scale R&D through commercial production, leveraging two integrated sites in Budapest and Miskolc.

Product overview

SONEAS Chemicals is a leading European CDMO (Contract Development and Manufacturing Organization) offering a comprehensive portfolio of chemical services for the pharmaceutical industry. The company operates through four core service pillars—Discovery Services (early phase development with synthesis and lead optimization), Process R&D (scale-up and process optimization), GMP Manufacturing (cGMP-compliant API and intermediate production), and Large Scale Manufacturing (commercial quantity production)—supported by five enabling services: Quality Assurance, Quality Control/Analytical Support, Health and Safety, Project Management & Sales, and Supply Chain Management. The company also offers three unique technology platforms: Hydrogenation, Hydroxyethylation, and Metathesis. With over 25 years of experience and three Budapest sites (R&D laboratories, pilot/GMP plant, and large-scale manufacturing facility), SONEAS provides end-to-end solutions from preclinical development through commercial supply.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 208,000 kg manufacturing capacity
• +1 more outcomes

Segments2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Uquifa GroupcoreStrategic or Co-development Partner · 1 January 2018SONEAS Chemicals became a member of the Uquifa Group in 2018. Uquifa is a global pharmaceutical company with headquarters in Barcelona, Spain, and additional facilities in Mexico. This membership positions SONEAS as part of a larger pharmaceutical services organization with expanded capabilities and reach.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Carbogen Amcis: Carbogen Amcis is a Swiss-headquartered CDMO focused on API development and manufacturing, including highly potent and complex small molecules. Its service portfolio from process R&D through commercial manufacture closely mirrors SONEAS's offering.
• Hovione: Hovione is a closely comparable Portugal-headquartered CDMO specializing in small-molecule API development and cGMP manufacturing, including particle engineering and complex chemistries. Both compete for the same European originator-pharma customer base across discovery-to-commercial scopes.
• CordenPharma: CordenPharma is a global CDMO with strong European manufacturing for APIs, peptides, and highly potent compounds. It directly competes with SONEAS for small-molecule custom synthesis and cGMP API contracts across Phase I–III and commercial supply.
• Fareva Group: Fareva is a France-headquartered CDMO with API and drug-product manufacturing across Europe, serving originator and generic pharma. It is a comparable mid-to-large European peer for small-molecule CDMO services.
• Aenova Holding: Aenova is a leading European CDMO offering API development, formulation, and manufacturing services, with a similar mid-sized and customer-focused profile to SONEAS. It competes head-to-head in small-molecule API CDMO services for European pharma customers.

Broad incumbents

• Lonza: Lonza is the world's largest CDMO across small molecules and biologics. It operates at a vastly different scale but overlaps directly with SONEAS in small-molecule API manufacturing, particularly for European innovator customers.
• Catalent: Catalent is a major global CDMO offering development and manufacturing across small molecules, biologics, and drug product. While much larger and more diversified, it competes with SONEAS for originator-pharma API and drug-substance contracts at commercial scale.
• Piramal Pharma Solutions: Piramal Pharma Solutions is a large global CDMO offering API manufacturing, drug product, and biologics services with facilities in North America, Europe, and Asia. It is a broader incumbent that competes with SONEAS for small-molecule API work at higher volume and with broader scope.

Emerging players

• Sai Life Sciences: Sai Life Sciences is an India-based CDMO providing discovery, process R&D, and cGMP API manufacturing to global pharma. It competes with SONEAS in the same end-to-end small-molecule CDMO space, often as a lower-cost alternative for Western customers.
• Eurofins CDMO (formerly Eurofins Discovery): Eurofins CDMO offers chemistry, discovery, and API manufacturing services globally, including in Europe. It is a comparable emerging peer across discovery chemistry and small-molecule manufacturing scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xlinkedin.com/company/soneas
• LinkedInlinkedin.com/company/soneas

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SONEAS Chemicals